Search research articles
Contact Us
Filters
Showing results (81-90 of 92) with videos related to
Page
of 10
Sort By:
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2011
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
D Rayson, T M Suter, C Jackisch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 92) with videos related to
Sort By:
Page
of 10
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2011
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial
D Rayson, T M Suter, C Jackisch, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Page
of 10